{"nctId":"NCT00566722","briefTitle":"Open Label Study of Adalimumab in Subjects Who Have a Sub-optimal Response to Systemic Therapy or Phototherapy","startDateStruct":{"date":"2008-01"},"conditions":["Psoriasis"],"count":152,"armGroups":[{"label":"Open Label","type":"EXPERIMENTAL","interventionNames":["Biological: adalimumab"]}],"interventions":[{"name":"adalimumab","otherNames":["ABT-D2E7","Humira"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of chronic plaque psoriasis with disease duration of at least 6 months\n* Sub-optimal response to treatment with etanercept, methotrexate, or narrow-band UVB phototherapy\n\nExclusion Criteria:\n\n* Prior treatment with adalimumab\n* Multiple concomitant therapy restrictions and/or washouts (topicals, ultraviolet, other systemic psoriasis therapies)\n* Prior treatment with natalizumab\n* Concurrent active skin diseases/infections\n* Poorly controlled medical conditions\n* History of neurologic symptoms suggestive of central nervous system (CNS) demyelinating disease\n* History of certain cancers","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants Who Achieved a Physician's Global Assessment (PGA) of Clear (0) or Minimal (1) at Week 16","description":"The PGA is a 6-point scale used to measure the severity of a patient's disease. Plaque elevation, scaling, and erythema are rated from 0= clear (no plaque elevation; no scaling; erythema=hyperpigmentation, pigmented macules, diffuse faint pink or red coloration) to 5=very severe (plaque elevation=very marked; scaling=very coarse; erythema=very severe \\[extreme red coloration, dusky to deep red coloration\\]).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"14","spread":null},{"groupId":"OG002","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving a PGA of Clear (0) at Week 16","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving at Least 1 Grade of Improvement in PGA at Week 16 Compared to Screening","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"59","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving 0 or 1 on Patient's Global Assessment at Weeks 2, 4, and 8","description":"The Patient's Global Assessment of Psoriasis-Severity is a rating of how well their disease is controlled. 0=complete disease control; 1=good disease control; 2=limited disease control; 3=uncontrolled disease.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"7","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"13","spread":null},{"groupId":"OG002","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Dermatology Life Quality Index (DLQI) Total Score","description":"The DLQI has 10 items and 6 subscales: symptoms and feelings (Q 1 and 2), daily activities (Q 3 and 4), leisure (Q 5 and 6), work and school (Q 7), personal relationships (Q 8 and 9), and treatment (Q 10). Participants rate how much their skin problem affected their life in previous week. Responses are 0 (not at all) to 3=very much. DLQI=total of scores for all items; max=30; min=0.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"5.89"},{"groupId":"OG001","value":"-5.2","spread":"5.45"},{"groupId":"OG002","value":"-3.3","spread":"4.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.0","spread":"7.45"},{"groupId":"OG001","value":"-6.5","spread":"6.44"},{"groupId":"OG002","value":"-3.8","spread":"5.66"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Achieving DLQI Total Score of 0 at Week 4 and Week 16","description":"DLQI total score of 0 indicates psoriasis had no effect at all on participant's life.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"6","spread":null},{"groupId":"OG002","value":"17","spread":null}]}]}]},{"type":"SECONDARY","title":"Psoriasis-related Pruritus Assessment","description":"The Psoriasis-related Pruritus Assessment is a scale for evaluating pruritus-related to psoriasis over the previous week; values range from 0 (no itching) to 10 (severe itching). A decrease in score indicates an improvement in pruritus.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"3.90"},{"groupId":"OG001","value":"-3.0","spread":"2.96"},{"groupId":"OG002","value":"-1.7","spread":"3.24"}]}]}]},{"type":"SECONDARY","title":"Visual Analog Scale (VAS) for Pain Involving Psoriatic Plaques and/or Psoriatic Arthritis","description":"The participant rates his/her pain during the previous week on a 100 mm VAS, from 0=no pain to 100=pain as bad as it could be. A decrease in score indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.7","spread":"24.41"},{"groupId":"OG001","value":"-21.4","spread":"30.01"},{"groupId":"OG002","value":"-12.7","spread":"29.90"}]}]}]},{"type":"SECONDARY","title":"Percent Work Time Missed Due to Psoriasis","description":"Work and activity impairment due to psoriasis were evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP), a 6-item questionnaire that measures effect of psoriasis on number of hours worked and the number of hours missed from work. It also measures the effect on productivity and regular activities: 0=no effect on work/daily activities; 10=psoriasis prevented me from working/doing daily activities. Decreases in values on each part indicate improvement. At Screening, percent time missed in the previous week ranged from 0% to 40%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"3.43"},{"groupId":"OG001","value":"1.3","spread":"4.75"},{"groupId":"OG002","value":"-0.1","spread":"1.85"}]}]}]},{"type":"SECONDARY","title":"Percent Overall Work Impairment Due to Psoriasis","description":"Percent overall work impairment was evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) (described above). At Screening, overall impairment ranged from 0% to 94%. A decrease in percent overall work impairment indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","spread":"28.06"},{"groupId":"OG001","value":"-6.4","spread":"19.75"},{"groupId":"OG002","value":"-2.8","spread":"16.92"}]}]}]},{"type":"SECONDARY","title":"Percent Impairment While Working Due to Psoriasis","description":"Percent impairment while working was evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP), described above. At Screening, impairment while working ranged from 0% to 90%. A decrease in percent impairment indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.5","spread":"30.31"},{"groupId":"OG001","value":"-8.0","spread":"19.35"},{"groupId":"OG002","value":"-1.5","spread":"18.46"}]}]}]},{"type":"SECONDARY","title":"Percent Activity Impairment Due to Psoriasis","description":"Percent impairment in regular activities was evaluated using the Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP), described above. At Screening, activity impairment due to psoriasis ranged from 0% to 90%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.3","spread":"33.08"},{"groupId":"OG001","value":"-12.2","spread":"25.62"},{"groupId":"OG002","value":"-4.7","spread":"23.03"}]}]}]},{"type":"SECONDARY","title":"Sleep Problems Index II","description":"Sleep Problems Index of the Sleep Scale from the Medical Outcomes Study reflects sleep disturbance, perceived sleep adequacy, daytime somnolence, and awakening short of breath or with headache. Participant rates each item from \"none of the time\" to \"all of the time\" for the previous 4 weeks. Scores are transformed to 0 to 100 scale; lower scores indicate less impairment. Decrease in score indicates improvement.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.7","spread":"18.01"},{"groupId":"OG001","value":"-7.7","spread":"15.82"},{"groupId":"OG002","value":"-2.0","spread":"14.57"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":41},"commonTop":["Upper respiratory tract infection","Fatigue","Nasopharyngitis","Injection site erythema","Headache"]}}}